about
Thiazide-associated hyponatremia in the elderly: what the clinician needs to knowAdverse Effects of GLP-1 Receptor AgonistsMANAGEMENT OF ENDOCRINE DISEASE: Hypothyroidism-associated hyponatremia: mechanisms, implications and treatmentPitavastatin and carbohydrate metabolism: what is the evidence?Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Ten common pitfalls in the evaluation of patients with hyponatremia.Combination drug treatment in obese diabetic patientsDapagliflozin in patients with type 2 diabetes mellitus.The effects of orlistat on metabolic parameters and other cardiovascular risk factors.A review of the metabolic effects of sibutramine.High density lipoprotein and cardiovascular diseases.Effects of glucagon-like peptide-1 receptor agonists on renal functionDifferences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study.Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering.Combination of fenofibrate with non-statin drug regimens.Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Treatment of hyponatremia: the role of lixivaptan.Correction of hypovolemia with crystalloid fluids: Individualizing infusion therapy.Safety considerations with fenofibrate/simvastatin combination.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Evaluation and treatment of hypernatremia: a practical guide for physicians.The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.Electrolyte disorders associated with the use of anticancer drugs.Ten pitfalls in the proper management of patients with hyponatremia.Cholesteryl ester transfer protein inhibitors: challenges and perspectives.Hyponatremia in patients with liver diseases: not just a cirrhosis-induced hemodynamic compromise.Role of ezetimibe in non-alcoholic fatty liver disease.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Use of intravenous fluids/solutions: a narrative review.Pharmacological management of diabetic dyslipidemia.Combination drug treatment in patients with non-alcoholic fatty liver disease.Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome.The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.Plasma triglyceride levels and body mass index values are the most important determinants of prebeta-1 HDL concentrations in patients with various types of primary dyslipidemia.Increased plasma visfatin concentration is a marker of an atherogenic metabolic profile.Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia.Hyponatremia in the elderly: challenges and solutions.Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.
P50
Q26750662-55DF405D-23E8-443A-9283-9464A01AB71EQ26801346-D9D3FDEC-CA2D-4A58-9BF6-E018FEC15ADCQ28067954-97EE0B20-2EC1-4B89-84FF-D16829AB01F3Q30251801-C369484B-62F2-402F-A6A3-1209E20D2FEBQ33776187-81404398-E592-413D-86BE-9ECA350B064FQ34506589-F60E9A5E-8F6A-4A86-AF87-1CB3DF525FEBQ34877652-21EC2CA6-A325-4B0B-9883-7615B8C03C53Q35064363-5EC34D1E-F6D5-460D-A9E2-980B6172A6B7Q36085597-3EA5A61B-CFB4-4DF9-B09D-8CEF2928397BQ36089487-F1012AB4-D5C8-4E9B-8775-684707BBFCE2Q37043222-381441D0-7D78-45FC-9570-CC64FACD6339Q37232679-FFC6B1C0-4660-4CC0-A505-C7E33FAD913FQ37321888-272086BF-80E5-4447-B092-169AF99E1855Q37702056-5359026E-B1E1-4D88-A10A-631F67401F7CQ37785562-D7E0E984-7345-49D6-AE39-151B0AD01968Q37898699-18F0B869-C73E-4AD3-B421-6170BD43AC5CQ37981299-7F5FD8B6-72FF-4005-893F-0F6B81169B60Q38205588-68925C48-C861-4816-AF94-32027860BEA6Q38207110-7DE2460D-86E6-4C61-AA6D-D6772C68A185Q38392108-DA62C0F6-1DB2-4238-8D5D-38E0B5D82261Q38541832-96DBE395-C74A-4C54-B305-E9AA8AAEE54BQ38658251-30548B0F-15EF-4F80-8940-A2B01B9CC161Q38712446-F61D580A-988D-49CF-BECD-26E41FE0EAE3Q38742876-4F9C479C-CB23-4CC8-8435-9EA97243569AQ38759414-917D03BB-1F34-42D4-BCE6-AC1846F82C0DQ38827652-F0B9A687-7EFC-4B15-9672-A03B073F9BA9Q38832774-E5F830D0-170A-49C6-ACDC-C60660CF49C1Q38872318-0954F397-6A9E-4FF0-A775-A91325A0F6FDQ38941024-91C3F78A-B991-42C7-B2F1-9BE94289AC26Q39000587-DED7FA54-5AE1-471A-9531-94F1D4BA8202Q39009861-D415E4CD-0FA0-4216-B318-DDE4B652ABD9Q39015072-3235911A-E2FC-4ED3-81A9-B224E19CE5D6Q41128646-F9D3EF7F-B627-4B4A-9925-341FBEA1E5ECQ42752715-60EBC7EC-46C8-494D-97FA-24CF7348FFBDQ43105087-4FC2ABA5-081B-42DF-99B1-D79325FECA3CQ43291590-B593C009-EC07-491B-A591-EDDA6C54C423Q44797396-9ED0AEAE-CBFA-4BA2-A23C-62F20E7094FEQ45990981-2E666530-AA2A-494B-9F57-02D6D41124C6Q46064949-14FB7F31-9F30-43D3-9B2C-F4E140B5B244Q46290681-748F89EE-526F-4433-9617-1125C5B5259F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Theodosios D. Filippatos
@ast
Theodosios D. Filippatos
@en
Theodosios D. Filippatos
@es
Theodosios D. Filippatos
@sl
type
label
Theodosios D. Filippatos
@ast
Theodosios D. Filippatos
@en
Theodosios D. Filippatos
@es
Theodosios D. Filippatos
@sl
prefLabel
Theodosios D. Filippatos
@ast
Theodosios D. Filippatos
@en
Theodosios D. Filippatos
@es
Theodosios D. Filippatos
@sl
P1053
I-6016-2016
P106
P1153
10044545000
P21
P2798
P31
P3829
P496
0000-0002-1713-0923